OneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an €11m Series A financing led by Amsterdam-headquartered life sciences investor LSP.
Illumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.
Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response.
A clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients.
In the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG.
AbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats.
Evox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases.
Swedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.
Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
NodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.